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The HIV-1 envelope gp120, which features both the
virus receptor (CD4) and coreceptor (CCR5/CXCR4)
binding sites, offers multiple sites for therapeutic
intervention. However, the latter becomes exposed,
thus vulnerable to inhibition, only transiently when
the virus has already bound cellular CD4. To pierce
this defense mechanism, we engineered a series
of heparan sulfate mimicking tridecapeptides and
showed that one of them target the gp120 coreceptor
binding site with mM affinity. Covalently linked to
a CD4-mimetic that binds to gp120 and renders the
coreceptor binding domain available to be targeted,
the conjugated tridecapeptide now displays nano-
molar affinity for its target. Using solubilized core-
ceptors captured on top of sensorchip we show
that it inhibits gp120 binding to both CCR5 and
CXCR4 and in peripheral blood mononuclear cells
broadly inhibits HIV-1 replicationwith an IC50 of 1 nM.
INTRODUCTION
Although tremendous progress has been made in the develop-
ment of antiviral drugs to treat human immunodeficiency virus
(HIV-1) infection (De Clercq, 2007) and despite the availability
of some 25 approved antiretroviral compounds (most of which
target HIV-1 enzymes), the virus continues to be amajor concern
and remains one of the leading causes of death worldwide. The
rapid emergence of drug-resistant viral strains, the inability
of current therapy to completely eradicate the virus, and the
strong adverse side effects associated with their long-term use
(Shafer and Schapiro, 2008) compromise treatment in patients
benefiting from these therapies and make the development of
new therapeutic options of utmost importance (Flexner, 2007).
Inhibition of HIV-1 entry, a process based on the sequential inter-
action of the viral glycoprotein (gp120) with the cell surface CD4
(Klatzmann et al., 1984) and either one of the two chemokine
receptors CCR5 or CXCR4 (Alkhatib et al., 1996; Feng et al.,Chemistry & Biology 19, 1311996), holds particular promise in addressing complications of
current therapy and has become a compelling target for control-
ling viral replication (Tilton and Doms, 2010). The recent approval
of maraviroc, a CCR5 antagonist (Dorr et al., 2005; Maeda et al.,
2004), has validated entry inhibition as a viable approach.
However, to avoid the selection of pre-existing and more patho-
genic CXCR4-using HIV-1 (for which no effective antagonistic
inhibitors yet exist) maraviroc has been licensed for the treat-
ment of patients infected with viral strains using CCR5 only.
On the virus side, the gp120 constitutes the central element for
all interactive events occurring during the pre-entry steps. A
wealth of evidence has shown that gp120 binding to CD4 not
only permits virus attachment, but also triggers extensive
conformational changes of the envelope that fold and/or expose
a four-stranded b sheet, known as the CD4-induced (CD4i)
domain (Wu et al., 1996). Being critically involved in CCR5/
CXCR4 recognition and highly conserved, this domain repre-
sents an attractive pharmacological target. Although inhibition
of protein-protein interactions is clearly challenging, a striking
feature of the CD4i domain is its basic nature (Kwong et al.,
1998; Rizzuto et al., 1998) and, not surprisingly, many of this
domain’s ligands are characteristically acidic. This includes
peptides selected by phage display screening (Dervillez et al.,
2010), sulfated oligosaccharides from the heparan sulfate (HS)
family (Crublet et al., 2008; Vive`s et al., 2005), aptamers (Cohen
et al., 2008), peptides derived from neutralizing antibodies (Dorf-
man et al., 2006), compounds issued from in silico screening of
molecular libraries (Acharya et al., 2011), or peptides derived
from the N-terminal sequence of CCR5 itself that comprise sul-
fotyrosines importantly contributing to gp120 binding (Cormier
et al., 2000; Farzan et al., 2000). The cryptic nature of this CD4i
surface prior to CD4 binding, however, limits its accessibility
both temporally and spatially andmakes it a relatively intractable
pharmacological target. In that context, we recently devel-
oped a class of compounds, in which a CD4 mimetic peptide
(mCD4) was linked to a HS dodecasaccharide (HS12), and
showed that mCD4 exposed the gp120 CD4i domain and
renders it available to be blocked by the HS12 oligosaccharide
(Baleux et al., 2009).
Here, to further develop this concept we engineered a series
of tridecapeptides that mimic HS, the synthesis of which,–139, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 131
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Figure 1. Ligand Binding to CCR5 and
CXCR4 Immobilized Sensorchips
Carboxy-terminal C9 tagged CCR5 or CXCR4
were solubilized from Cf2Th cells and captured on
top of a mAb 1D4 activated CM4 sensorchip.
CCR5 (left) and CXCR4 (right) ligands were in-
jected over the coreceptor surfaces, and the
binding responses (in RU) were recorded as
a function of time (in S). Binding of 25 nM of mAb
2D7 (blue) and mAb 12G5 (red) to CCR5 (A) and
CXCR4 (B). Binding of YU2 gp120 (black), YU2/
mCD4 (blue), or YU2/mCD4/maraviroc (red) to
CCR5 (C) or MN gp120 (black), MN/mCD4 (blue),
or MN/mCD4/AMD3100 (red) to CXCR4 (D).
Binding of the equimolar complex of YU2/mCD4
at (from top to bottom) 100, 66, 44, 29, 19, and
12.5 nM to CCR5 (E) or equimolar complex of
MN/mCD4 at (from top to bottom) 225, 150, 100,
66, 44, and 29 nM to CXCR4 (F). The black traces
correspond to the experimental data, and the red
traces correspond to the fitted data using a 1:1
langmuir model. Binding of YU2 or MN gp120
(100 nM) preincubated with 100 nMofmCD4 (blue)
or mCD4-HS12 (red) to CCR5 (G) or CXCR4 (H).
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Novel gp120 Targeting HIV-1 Entry Inhibitoralthough amenable to large-scale production, remains extraor-
dinary complex (Dilhas et al., 2008). We then set up a binding
assay in which detergent solubilized CCR5 and CXCR4 were
both functionally captured on top of sensorchips and used
them to show that, conjugated to a mini CD4, a HS mimicking
peptide efficiently targets the CD4i domain of gp120 and blocks
its interaction with the coreceptors. This compound displays
antiviral activity against LAI and Ba-L HIV strains with an IC50
as low as 1 nM, two to four orders of magnitude lower than
the above-described anionic compounds. To our knowledge,
this is the most potent gp120 targeting molecule, with the
unique property to simultaneously block two critical and
conserved regions of gp120. Importantly it inhibits CCR5 and
CXCR4 using viruses equally well, and is also highly active
against a number of viral primary clinical isolates. These results
should have strong implications for the development of a new
anti-HIV-1 therapy.132 Chemistry & Biology 19, 131–139, January 27, 2012 ª2012 Elsevier Ltd All rights reserveRESULTS
HIV-1 Coreceptors Immobilization
and gp120 Binding
Assessing the ability of molecules to
target the coreceptor binding site of
gp120would strongly benefit fromadirect
coreceptor-gp120 interaction assay. To
that end, both HIV-1 coreceptors were
solubilized from Cf2Th cells, recombi-
nantly expressing either CCR5 or CXCR4,
using a specific cocktail of lipids and
detergents that was adapted from that
previously described (Navratilova et al.,
2005). Solubilized coreceptors, which
feature a C-terminal C9 tag (Babcock
et al., 2001; Mirzabekov et al., 1999)
allowing their oriented capture with thecognate 1D4 antibody, were immobilized on top of a sensorchip
to a level of 4,000 resonance units (RU). To verify whether the
coreceptors remained functional, we first investigated their
binding capacity with the conformationally sensitive mAb 2D7
for CCR5 (Khurana et al., 2005; Lee et al., 1999) and 12G5 for
CXCR4 (Baribaud et al., 2001). As shown in Figures 1A and 1B,
injection of these mAbs over the CCR5 and CXCR4 functional-
ized surfaces gave rise to strong and coreceptor-specific
binding signals, indicating both the presence of the coreceptor
on the surface and the integrity of the corresponding epitopes.
Following this, we analyzed whether the immobilized corecep-
tors bound gp120, in a CD4-dependent manner. For that
purpose, 100 nM of either YU2 or MN (R5 and X4 envelopes
respectively), in the absence or presence of mCD4, a CD4
mimetic peptide that was previously found to bind gp120 and
induce the conformational change that lead to the folding/
exposure of the coreceptor binding site (Baleux et al., 2009),d
CD4BS ligand 
CoRBS ligand 
X S(XDXS)3 name 
YSO3 P3YSO3
pF P3pF 
Asu P3Asu 
Y P3Y 
Figure 2. mCD4-S(XDXS)3 Constructs
A miniCD4 was used as a CD4 binding site (CD4BS) ligand and covalently
conjugated through an appropriate linker to S(XDXS)3 peptides investigated as
potential coreceptor binding site (CoRBS) ligands. S and D are serine and
aspartic acid residues respectively and X is either a sulfotyrosine (YSO3),
a p-carboxymethyl phenylalanine (pF) an aminosuberic acid (Asu) or a
tyrosine (Y). See also Figures S1 and S2 and Table S1.
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Novel gp120 Targeting HIV-1 Entry Inhibitorwas injected over the coreceptor surfaces. Both envelopes inter-
acted with their coreceptors, presumably because the CD4i
epitope is transiently exposed on the dynamic structure of
gp120, as already observed with anti-CD4i antibodies (Thali
et al., 1993). The binding responses, however, were significantly
enhanced by the presence of mCD4 and efficiently inhibited
by 1 mM of maraviroc or AMD3100 (Figures 1C and 1D), two
compounds targeting CCR5 and CXCR4 respectively, and
having anti-HIV-1 activity (Tilton and Doms, 2010). Next, dose-
response experiments were performed with mCD4:gp120 ratios
fixed at 1:1 and injected over the immobilized CCR5 or CXCR4
surfaces. Sensorgrams were obtained for both envelopes
(Figures 1E and 1F), which evaluations (see Supplemental
Experimental Procedures) returned estimated affinities of
11.5 ± 2.9 nM and 154 ± 68 nM for CCR5 and CXCR4, respec-
tively. These values were identical to that reported by a similar
technique (Navratilova et al., 2005) or radioligand binding assay
with cell membrane-embedded CCR5 (Doranz et al., 1999) as
to that reported for CXCR4, using proteoliposome embedded
coreceptors and radiolabeled gp120 (Babcock et al., 2001).
We previously reported that the gp120 CD4i epitope can be
targeted by HS (Crublet et al., 2008; Vive`s et al., 2005), and
that a HS dodecasaccharide covalently linked to mCD4
(mCD4-HS12) binds gp120 and blocks its subsequent interaction
with mAb 17b (Baleux et al., 2009). mAb 17b belongs to a group
known as ‘‘anti-CD4i’’ antibodies, which recognizes a conserved
element of gp120, induced by CD4 and partially overlapping the
coreceptor binding site (Xiang et al., 2002). We thus made use of
the coreceptor binding assay described above to investigate
whether mCD4-HS12 would also inhibit gp120 binding to CCR5
and CXCR4. As shown in Figures 1G and 1H, both YU2 and
MN gp120 in complex with mCD4-HS12 featured a strongly
reduced ability to recognize CCR5 or CXCR4 compared to that
of gp120 in complex with mCD4 alone. This suggests that
such molecules could serve as lead compounds for the future
development of a new class of entry inhibitors.
Chemical Synthesis of mCD4 Linked HS Mimetic
Peptides
HSs are, however, notoriously difficult to synthesize. In addition,
their inherent sequence heterogeneity, in terms of sulfation
pattern and saccharide composition, would currently make the
preparation of a dodecamer series out of reach. Thus, based
on the mCD4-HS12 template, we tested the hypothesis that
the HS moiety could be mimicked by peptides, the chemical
synthesis of which is more straightforward, and more easily
amenable to sequence-activity relationship investigation. To
display the functional hydroxyl, carboxyl, and sulfate groups
that characterize HS, peptides comprising Ser, Asp, and Tyr,
the latter being possibly sulfated, were considered. This strategy
is supported by the observation that a SYDY tetrapeptide binds
to the HS binding domain of the vascular endothelial growth
factor (Maynard and Hubbell, 2005) and that phage display
screenings against the CD4i epitope of gp120 returned
sequences enriched in YD motifs (Dervillez et al., 2010). It is
also worth noting that a number of antibodies against the
gp120 coreceptor binding domains feature sulfotyrosines in their
paratope, as does the N terminus of both CCR5 and CXCR4
(Choe et al., 2003).Chemistry & Biology 19, 131Building of a S(XDXS)n sequence (were X stands for different
possible amino acids; see below) using the peptide builder of
Hyperchem 5, showed that a 13 amino acid peptide (n = 3), in
its extended configuration (4, c, and u angles set to 180) would
have a length equivalent to the HS 12 mer (data not shown).
Thus, a tridecapeptide, alternating OH/COO- and OH/SO3
-
groups, having the sequence: SYSO3DYSO3SYSO3DYSO3SYSO3
DYSO3S (X being in this case a sulfotyrosine; YSO3) was first
synthesized (P3YSO3). The nonsulfated equivalent (P3Y) was
also prepared along with a number of other peptides in which
X was replaced by p-carboxymethyl phenylalanine (P3pF) or
aminosuberic acid (P3Asu), two residues that have been shown
to functionally mimic sulfotyrosine in cholecystokinin type B
receptor ligand CCK8 (McCort-Tranchepain et al., 1992) and
sulfakinins (Nachman et al., 2005). A tridecaglutamate (display-
ing 13 carboxylic groups) was also prepared (E13) as a nonspe-
cific poly anionic peptide (Figure 2). In order to maintain an
appropriate distance between mCD4 and these peptides,
enabling the final molecule to reach both the CD4 and corecep-
tor binding sites, a g-aminobutyric acid (g-Abu) was introduced
on their N terminus. These peptides were derivatized with
S-acetylthiopropionic acid to allow the coupling to Lys5 of a
maleimide-activated mCD4. All compounds were purified to
a level of 95% by RP-HPLC (see Table S1 and Figures S1
and S2 available online), controlled by mass spectrometry and–139, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 133
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BA Figure 3. The S(XDXS)3 HS Mimetic Peptides
Coupled to mCD4 Inhibit gp120-CD4, gp120-mAb
17b, and gp120-Coreceptor Interactions through
Binding to the CD4 and the Coreceptor Binding
Sites of gp120
Binding responses measured when YU2 (A) or MN (B)
gp120 at 100 nM, either alone (blue) or preincubated with
100 nM of mCD4 (pink), mCD4-P3Y (green), mCD4-E13
(turquoise), mCD4-P3pF (orange), mCD4-P3Asu (brown),
or mCD4-P3YSO3 (red) were injected over a CD4 activated
surface. YU2-mCD4 (C) or MN-mCD4 (D) complexes
(25 nM) were preincubated with 5 mM of HS12 (red),
P3YS03 (green), or the other HS mimetic peptides (none,
P3Y, E13, P3pF, and P3Asu; all in black) and injected over
a mAb 17b activated surface. The blue trace shows the
binding of gp120 to mAb 17b in the absence of mCD4. The
P3YSO3 peptide (E) or HS12 (F) at different concentrations
were coincubated with YU2-mCD4 (circle) or MN-mCD4
(square) and injected over a mAb 17b surface. The binding
response (mean of triplicate experiment) recorded at the
end of the injection phase was plotted versus the con-
centration of the inhibitors in mM. Overlay of sensorgrams
showing the injection of 100 nM of mCD4 (blue), mCD4-
P3Y (black) or mCD4-P3YSO3 (red), from 0 to 600 s, over
immobilized YU2 (G) orMN (H) gp120, after which 15 mg/ml
of mAb 17b was injected from 600 to 900 s. Binding of
YU2 or MN gp120 (100 nM) preincubated with 100 nM of
mCD4 (blue) or mCD4-P3YSO3 (red) to CCR5 (I) or CXCR4
(J). In all graphs, binding signals were recorded in RU as
a function of time (S).
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Novel gp120 Targeting HIV-1 Entry Inhibitorquantified by amino acid analysis as described in the Supple-
mental Experimental Procedures.
mCD4 Linked HS Mimetic Peptides Inhibit Binding
of gp120 to CD4, mAb 17b, and Coreceptors
To verify that peptide conjugation did not prevent the ability of
mCD4 to interact with gp120, a competition assay was per-
formed, in which YU2 or MN were incubated with the different
mCD4 conjugates and injected over a CD4 functionalized
surface. Results showed that the mCD4 conjugates all very effi-134 Chemistry & Biology 19, 131–139, January 27, 2012 ª2012 Elsevier Ltd All rights rciently prevent gp120-CD4 interaction, with
greater potency than that of unconjugated
mCD4 (Figures 3A and 3B). Next, the capacity
of the anionic peptides to target the gp120
CD4i epitope was investigated by analyzing
their ability to prevent gp120 binding to mAb
17b, in the presence of soluble mCD4. While un-
liganded gp120 was not (MN) or only poorly
(YU2) recognized by mAb 17b (Figures 3C and
3D; blue trace), preincubation with mCD4
strongly promoted binding (black trace). When
the gp120-mCD4 complexes were further incu-
batedwith 5 mMof the above-described trideca-
peptides, strong inhibition was observed for
P3YSO3 (green trace). The tridecaglutamate
(E13) was devoid of activity, indicating that the
anionic character of the peptide is not sufficient
to provide binding, as were the unsulfated P3Y
or the sequence in which the sulfotyrosine
mimetics (pF and Asu) were introduced (Figures3C and 3D, black traces). HS12 (red trace) also fully blocked
mAb17b binding to MN-, but not to YU2-gp120. Together, this
showed that among the different peptides investigated only the
SYSO3DYSO3 motif competes with mAb 17b to interact with the
gp120 CD4i domain. To better quantify the inhibitory activity of
this peptide, the same assay was run, with a range of P3YSO3
concentrations, and compared with HS12. A similar concentra-
tion dependency was observed on both R5 (YU2) and X4 (MN)
envelopes, with IC50 of 2.9 and 3.1 mM, respectively, indicating
that, interestingly, P3YSO3 interacts with gp120 independentlyeserved
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Figure 4. Antiviral Activity of mCD4 Linked to Either HS12 or
S(XDXS)3 HS Mimetic Peptides
PHA-P-activated PBMCs were infected with either (A) LAI (X4 tropic) or
(B) Ba-L (R5 tropic) HIV-1 strains, preincubated with each of the drugs under
investigation (1:5 dilutions between 500 nM and 320 pM). Molecules and
viruses were maintained throughout the culture, and cell supernatants were
collected at day 7 postinfection. Reverse transcriptase activity was quantified
from which 50 (black), 70 (gray), and 90% (white) effective doses (ED) were
calculated. In the absence of the inhibitory compounds, the RT level was in the
range of 10,000–25,000 and 6,500–10,000 pg/ml (depending on the donor) for
LAI and Ba-L strains respectively. Data are represented as mean of triplicate
experiments (±SEM) performed on PBMCs from three to four donors. See also
Table S2.
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Novel gp120 Targeting HIV-1 Entry Inhibitorof coreceptor tropism. In contrast, HS12 strongly inhibited the
interaction between MN and mAb 17b (with a concentration as
low as 0.5 mM) but was ineffective toward YU2, at concentrations
up to 10 mM (Figures 3E and 3F). Next, to determine the binding
mechanism of the mCD4-S(XDXS)3 constructs, X4- and R5-
gp120 were immobilized on a sensorchip and first allowed to
bind to mCD4, mCD4-P3Y, or mCD4-P3YSO3. The resulting
complexeswere then probedwithmAb 17b, the binding of which
being a marker of the coreceptor binding site accessibility. As
expected, mCD4 binding to gp120 renders the coreceptor
binding site accessible, a point that was also observed, although
with a lower efficiency, withmCD4-P3Y. These data indicate that
while mCD4-P3Y bound to gp120, the unsulfated peptide did not
sufficiently interact with the newly available surface to blockmAb
17b recognition. In contrast, when mCD4-P3YSO3 was used
instead of mCD4 or mCD4-P3Y, the mAb 17b was no longer
able to interact with the complex. Altogether, these data thus
support the view that mCD4 first binds to gp120 and exposes
the coreceptor binding site, with which the P3YSO3 moiety
then interacts strongly enough to prevent antibody binding
(Figures 3G and 3H). Finally, using the direct gp120-coreceptor
interaction assay described in Figure 1, we also demonstrated
that mCD4-P3YSO3 very potently inhibits gp120 binding to
both CCR5 and CXCR4 (Figures 3I and 3J). This suggests that
this compound could be a coreceptor independent HIV-1 entry
inhibitor.
mCD4 Linked P3YSO3 Peptides Display Strong Antiviral
Activity
Having characterized the binding mechanism of these com-
pounds, we investigated whether these anionic peptides, either
conjugated or not to mCD4 displayed anti-HIV-1 activity. This
was performed using an assay in which viral replication was
measured (reverse transcriptase quantification) in the superna-
tant of blasted peripheral blood mononuclear cells (PBMCs) iso-
lated from three to four donors and infected by either of the HIV-1
reference strains R5 (Ba-L) or X4 (LAI). When used alone, none of
the peptides demonstrated antiviral activity at the highest con-
centration tested (500 nM; data not shown). However, when
conjugated to mCD4, they displayed inhibitory activity against
the LAI strain, with effective doses giving 50% inhibition (ED50)
as low as 0.5 nM for mCD4-P3YSO3, which compares well to
1.4 nM for mCD4-HS12. Consistently with the biochemical
data, the importance of the sulfate groups was shown by
the large increase of ED50 (98 nM) that characterized mCD4-
P3Y, whereas the other anionic peptides (mCD4-P3pF, mCD4-
P3Asu, and mCD4-E13) displayed 8.2–30 nM ED50 (Figure 4A).
The Ba-L strain was also very strongly inhibited by mCD4-
P3YSO3, with an ED50 of 1.3 nM versus 18 nM for mCD4-HS12.
None of the other conjugates displayed significant antiviral
activity (Figure 4B). AZT, used as a reference anti-HIV molecule
in the same assay returned ED50 of 8.7 and 11 nM for R5 and X4
viruses, respectively (Figures 4A and 4B).
We also observed that mCD4-P3YSO3 does not need to be
preincubated with the virus to be active. Indeed, addition of
the molecule either to the cells prior to the viral challenge or to
the virus prior to the cell infection return identical results (Table
S2). This is consistent with the high affinity this molecule displays
for the viral envelope, presumably enabling a fast binding to itsChemistry & Biology 19, 131target, and also suggests a potential use of this kind of
compounds as a microbicide, a condition in which inhibitors
are present within the host tissues, before viral infection.
Having established that mCD4-P3YSO3 displayed very strong
antiviral activity against LAI and Ba-L HIV-1 strains, used as
model systems, we extended our investigations to using a series
of more clinically relevant primary strains, including 92UG029,
SF162, 92US723, 96USHIPS4, 92HT599, and 98IN017. As
shown in Table 1, mCD4-P3YSO3 displayed a high level of anti-
viral activity, characterized by ED50 in the range of 0.2–1.2 nM for
five of them and 29 nM for HIV-1 98IN017. As for the LAI and
Ba-L strains, the mCD4 or P3YSO3 were only poorly active or
inactive, further supporting the very strong synergistic effect
induced by the coupling strategy. None of themolecules showed
cytotoxicity at up to 1 mM (data not shown).–139, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 135
Table 1. Anti-HIV-1 activity of AZT, mCD4-P3YSO3, P3YSO3, and mCD4 against Clinical HIV-1 Isolates
Viral Strain
Clade-Tropism
92UG029
A-X4
SF162
B-R5
92US723
B-R5/X4
96USHIPS4
B-R5/X4
92HT599
B-X4
98IN017
C-X4
AZT ED50 7 ± 0 8 ± 7 8 ± 0.1 19 ± 9 9 ± 4 8 ± 3
ED70 16 ± 3 13 ± 8 17 ± 1 27 ± 11 22 ± 5 19 ± 5
ED90 61 ± 17 31 ± 3 59 ± 19 56 ± 15 110 ± 13 108 ± 25
mCD4-P3YSO3 ED50 0.2 ± 0.0 0.3 ± 0.2 0.3 ± 0.1 1.2 ± 1 0.5 ± 0.2 29 ± 18
ED70 0.3 ± 0.1 0.4 ± 0.3 0.35 ± 0.2 1.6 ± 1.2 1.3 ± 0.9 147 ± 9
ED90 0.8 ± 0.3 0.9 ± 0.2 0.45 ± 0.2 3 ± 1.4 3.5 ± 0.0 >500
P3YSO3 ED50 >500 >500 >500 >500 >500 >500
ED70 >500 >500 >500 >500 >500 >500
ED90 >500 >500 >500 >500 >500 >500
mCD4 ED50 403 ± 76 245 ± 155 23 ± 1 >500 355 ± 155 >500
ED70 >500 352 ± 105 34 ± 10 >500 >500 >500
ED90 >500 >500 52 ± 22 >500 >500 >500
The table shows the effective dose (ED, mean of triplicate determination), in nM (±SD) required to inhibit 50%, 70%, and 90% of HIV-1 replication.
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Targeting gp120 for HIV-1 inhibition is both attractive (because
the protein engages multiple interactions key to viral entry,
thus offering multiple sites for inhibition) and challenging (in the
entry complex, the buried surface to block comprises both
the gp120-CD4 and gp120-coreceptor interfaces). Although
protein-protein interfaces are often relatively featureless and
devoid of traditional cavities into which a small molecule can
dock, the realization that the gp120 coreceptor binding site
displays a restricted number of functionally important basic resi-
dues has very recently attracted the attention of many studies.
Many of them reported that anionic molecules target the CD4i
epitope, as shown by their ability to competitively inhibit mAb
17b binding with IC50 in the 1–100 mM range (Acharya et al.,
2011; Brower et al., 2009; Cohen et al., 2008; Cormier
et al., 2000; Crublet et al., 2008; Dervillez et al., 2010; Farzan
et al., 2000; Kwong et al., 2011; Seitz et al., 2010). HS belongs
to this class of CD4i domain targeting molecules (Crublet et al.,
2008), and a highly sulfated and regular sequence comprising
12 monosaccharide units has been recently prepared. Conju-
gated to mCD4, it displays strong anti-HIV-1 activity (Baleux
et al., 2009). However, HS is extraordinary complex and hetero-
geneous in sequence (Esko and Lindahl, 2001). Based on the 48
different units that the polymer theoretically comprises, a 12 mer
library would reach 1010 molecules. Although the reality is less
(all the combinations are not possible), it remains much more
than can be realistically synthesized for structure-activity rela-
tionship studies. Thus, to further develop this kind of molecule
we attempted to design HS mimetic peptides, with the general
sequence S(XDXS)3 and showed that, when X was a sulfotyro-
sine, it binds to the CD4i epitope, blocking mAb 17b with IC50
of 3 mM, thus comparing very well with the above-mentioned
molecules. Interestingly, this peptide interacts equally well with
R5 and X4 gp120, whereas HS especially binds to the X4 enve-
lope (Figures 3E and 3F). More importantly, the conjugation of
this peptide to mCD4 dramatically enhances its binding activity,
the conjugated molecule being able to fully prevent the gp120/
mAb 17b interaction at low nM concentration, showing that the136 Chemistry & Biology 19, 131–139, January 27, 2012 ª2012 Elsevcovalent linkage induced a strong synergistic effect. This is
consistent with the view that high-affinity mCD4 binding takes
place initially, inducing the exposure of the mAb 17b epitope to
which the sulfated peptide can then bind. As such, this molecule
is distinct from other mAb 17b blocking peptides that suppress
CD4 binding and subsequent coreceptor binding site exposure
through an allosteric inhibitory effect rather than competitive
inhibition (Biorn et al., 2004).
Although widely used as a CCR5 or CXCR4 surrogate, mAb
17b, however, only imperfectly defines the gp120 coreceptor
binding site which, in addition to theCD4 induced bridging sheet,
is also constituted by the V3 loop in particular (Dragic, 2001).
Thus, to better assess the blocking efficiency of molecules
targeting the gp120-coreceptor interaction, and taking into
account domains outside the CD4i epitope itself, CCR5 and
CXCR4 were solubilized and functionally captured on top of bia-
core sensorchips. Binding of gp120 to CCR5 and CXCR4 proved
to be both CD4 and concentration dependent and inhibited by
specific antagonists. Fitting of the binding data was expectedly
complicated by several parameters, such as the complexity of
the buffer system used, the reversible nature of both the
1D4-coreceptor and mCD4-gp120 complexes and the confor-
mational flexibility of gp120, thus the calculated affinity values
reported should probably be considered as estimates only.
Nevertheless, we report KDs of 10 and 150 nM for the YU2-
CCR5 and MN-CXCR4 interactions respectively, comparable
to those obtained with cellular systems in which the coreceptors
remained in their natural cell membrane environment (Babcock
et al., 2001; Doranz et al., 1999). This assay provides a useful,
label-free method, to identify both binding capacity of envelopes
and inhibitory activity of potential drugs. This was especially true
in the framework of this study investigating sulfated/polyanionic
compounds to target the gp120 coreceptor binding site.
Although tyrosine sulfation of coreceptors has been shown to
play a less significant role in CXCR4- than in CCR5-dependent
HIV-1 entry (Farzan et al., 2002), we found that when conjugated
to mCD4 the sulfated P3YSO3 displays very strong binding
activity toward both R5- and X4- gp120. Using this assay, we
indeed report that gp120 binding to both CCR5 and CXCR4ier Ltd All rights reserved
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P3YSO3. The overall positive charge of the V3 loop, which is
much higher in X4- than in R5-gp120 (Moulard et al., 2000)
strongly influences the electrostatic potential of the coreceptor
binding region of the protein. In the case of CXCR4-using
viruses, electrostatic interactions between the sulfated peptide
and the V3 loop may thus also participate in the blocking mech-
anism. This view is consistent with the fact that the V3 loop
(which importantly contributes to coreceptor binding) is located
close to the CD4i bridging sheet and with its known capacity to
interact with polyanions (Moulard et al., 2000). This is further sup-
ported by the observation that all the anionic peptides prepared
during the course of this study (mCD4-P3Asu, mCD4-P3pF,
mCD4-E13, and mCD4-P3Y) also display some level of antiviral
activity against X4- but not against R5- viruses. This also sug-
gests that, in engineering such compounds, it should be advan-
tageous to use sulfated peptides with only modest specificity so
that they can broadly target distinct envelopes, the high speci-
ficity of the conjugated bivalent compound being brought by
the mCD4 moiety. Structural studies of mCD4-P3YSO3, in
complex with different gp120 would be interesting approaches
to further define these aspects. In this regard, it can be noted
that sulfated peptides would represent an advantage over HS,
the crystallography of which, in complex with proteins appearing
to be specially challenging (Imberty et al., 2007).
Although relatively limited in molecular mass (5,500 Da) the
mCD4-P3YSO3 molecule has the remarkable property to target
two critical and conserved regions of gp120, and thus to simul-
taneously block two large protein surfaces (i.e., the CD4 and
the coreceptor binding site). In complete agreement with the
biochemical data, it displays 1 nM ED50 anti-HIV-1 activity, for
both CXCR4 and CCR5 using model viruses in a cellular assay.
Importantly, we also found that this compound had a broad
neutralizing activity and was very effective against a number of
HIV-1 clinical isolates, strongly suggesting that this approach
deserves further investigation toward in vivo evaluation. No
effective antagonistic inhibitors yet exist for CXCR4. This
compound, which at 1 mM is devoid of toxicity, could be a valu-
able weapon against the more aggressive CXCR4-tropic HIV-1
strains or for patients featuring a mixed HIV-1 population for
which CCR5 antagonist cannot be used.
SIGNIFICANCE
While very significant progress has been made in the devel-
opment of anti-HIV-1 drugs, the emergence of drug-resis-
tant viruses, the inability of current therapy to be curative,
and its adverse side effects have led to an urgent need for
new blocking strategies. As a target, gp120 that features
the coreceptor binding site is particularly attractive. How-
ever, its cryptic nature makes it a difficult target that up to
now has resisted attacks.
Here, we covalently linked a sulfotyrosine containing
tridecapeptide that targets the gp120 coreceptor binding
site, to a CD4 mimetic (mCD4). We showed that the mCD4,
in interacting with gp120, induces conformational changes
that expose the coreceptor binding site and renders it
available to be blocked by the sulfated peptide. In cellular
assays, this compound, which successfully targets twoChemistry & Biology 19, 131critical domains of gp120, displays strong antiviral activities
and neutralizes HIV-1 with 1 nM IC50.
The conjugate was much more effective than a mixture of
mCD4 and tridecapeptide alone, indicating that the covalent
linkage is essential to produce a synergistic effect. To our
knowledge, this compound establishes a new type of in-
hibitor and suggests a concept by which a relatively low
specific molecule (the sulfated peptide), coupled to a highly
specific compound (themCD4) can reach very high affinities
for its target. Combining these two characteristics may
enable the molecule to accommodate mutations that invari-
ably characterize acquired viral resistance.
These results should have strong implications for
the development of a new class of anti-HIV-1 therapy: the
mCD4-conjugate simultaneously blocks the attachment
and entry domains of gp120 and thus inhibits viral replication
at a very early stage of the viral life cycle. Most importantly, it
has the remarkable and unique property to neutralize both
CCR5- and CXCR4-tropic HIV-1. This is definitively a strong
advantage since HIV-1 may escape from CCR5 antagonists
through selection of CXCR4-using variants.EXPERIMENTAL PROCEDURES
Materials
A BIAcore 3000 machine, CM4 sensorchip, amine coupling kit and HBS-P
(10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20
[pH 7.4]) were from GE-Healthcare. Streptavidin and Piperidin were from
Sigma. MN and YU2 gp120 were from Immunodiagnostic. Soluble CD4,
mAb 17b and Cf2Th coreceptor expressing cells were obtained through the
NIH AIDS Research and Reference Reagent Program. The antibodies 12G5
and 2D7 were purchased from R&D systems and BD Pharmingen, respec-
tively. The HIV-1 entry inhibitors AMD3100 andMaraviroc were from Fernando
Arenzana (Pasteur Institute, Paris). The1D4 antibody was from Flint Box,
University of British Columbia. Synthetic phospholipid blend 1,2-dioleoyl-sn-
glycero-3-phosphocholine/1,2-dioleoyl-sn-glycero-3-phospho-L-serine for-
mulation (DOPC/DOPS; 7:3, w/w), the Mini-Extruder kit, filter supports and
polycarbonate filters with defined pore diameter (100 nm) were purchased
from Avanti Polar Lipids. Detergents, n-dodecyl-b-D-maltopyranoside
(DOM), 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane sulfonate/N,N-
Dimethyl-3-sulfo-N-[3-[[3a,5b,7a,12a)-3,7,12-trihydroxy-24-oxocholan-24-yl]
amino]propyl]-1-propanaminium (Chaps) and Cholesteryl hemisuccinate tris
salt (CHS) were purchased from Anatrace. Complete, EDTA-free protease
inhibitor tablets were from Roche Diagnostics. Polyethylene glycol 8,000
50% w/v solution was purchased from Hampton research. Resins for peptide
synthesis were purchased from RAPP Polymere GmbH and Fmoc AAs, HATU,
NMP, DMF, and TFA were from Applied Biosystems. Fmoc-Tyr (SO3.NnBu4)-
OH and Fmoc-g-Aminobutyric-OH (g-Abu) were from Novabiochem,
(S)-Fmoc-2-amino-octanedioc acid-8-ter-butyl ester (Asu) from Polypeptides,
and Fmoc -L-4 (O-tButylcarboxymethyl)-Phe-OH (pF) from Anaspec. HPLC
grade triethylamine acetate buffer was from GlenResearch. N-succinimidyl-
S-acetylthiopropionate (SATP) was from Pierce.
CCR5/CXCR4 Solubilization
The human receptors CCR5 and CXCR4, featuring a C-terminal C9 tag
(TETSQVAPA), were expressed in Cf2Th canine thymocyte cells as described
previously (Mirzabekov et al., 1999). The CCR5 and CXCR4 solubilization
protocol was adapted from a described procedure (Navratilova et al., 2005).
Briefly Cf2Th.CCR5- or CXCR4-expressing cells (5–8 3 106) were solubilized
in 1 ml buffer consisting of 100 mM (NH4)2SO4, 20 mM Tris-HCl (pH 7.5),
10% glycerol, 15% PEG 8000, protease inhibitors, CHS (0.2%), DOM
(1.5%), CHAPS (1.5%), and 0.33 mM DOPC:DOPS liposomes (see detailed
buffer preparation in the Supplemental Experimental Procedures). The cell
suspension was sonicated (6 3 1 s pulses) and placed on a rotating wheel–139, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 137
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centrifuged at 14,000 rpm for 30 min at 4C and the supernatants were either
used directly in SPR analysis or stored at 80C until further use.
Surface Plasmon Resonance-Based Binding Platform
The interactions between gp120 and its ligands (CD4, mAb 17b, CCR5, and
CXCR4) were analyzed by surface plasmon resonance (SPR) technology.
For that purpose, N-ethyl-N0-(diethylaminopropyl)-carbodiimide (EDC)/N-
hydroxy-succimide (NHS) activated CM4 sensorchips were functionalized
with either 1,200 RU of soluble CD4, 700 RU of mAb 17b, or 7,000 RU of
mAb 1D4 and blocked with pH 8.5 1 M ethanolamine. The C9-tagged CCR5
or CXCR4 were captured onto the 1D4 mAb to a level of 4,000 RU. In
some cases, gp120 were also immobilized onto CM4 sensorchip. For this,
MN (50 mg/ml in 5mMmaleate buffer [pH 6]) or YU2 (50 mg/ml in 10mMacetate
buffer [pH 4.8]) were injected at 5 ml/min over an EDC/NHS activated flow cell
until levels of 4,500 RU was obtained. Molecules under investigation were
injected over the different surfaces and the binding responses were recorded
as a function of time (see Supplemental Experimental Procedures).
Peptide Synthesis and Purification
Peptides were prepared by solid-phase peptide synthesis on H-Ser(tBu)-2-
ClTrt-PS-resin using Fmoc chemistry excepted for the E13 peptide which
was prepared on Fmoc-Glu(tBu)-PHB-PS-resin. Fmoc-Tyr-(SO3.NnBu4)-OH
was used to synthesize the sulfotyrosines containing peptide. SATP was
used to introduce a protected sulfhydryl groups at the N terminus of each puri-
fied peptide, which were then conjugated in presence of hydroxylamine to a K5
maleimide-activated mCD4, the synthesis of which has been reported else-
where (Baleux et al., 2009) to yield the desired conjugates mCD4-P3YSO3,
mCD4-P3Y, mCD4-P3pF, mCD4-P3Asu and mCD4-E13. All compounds
were purified by RP-HPLC. Analytical procedures, characterization, and quan-
tification of these materials are described in the Supplemental Information.
Antiviral Assay
Phytohemagglutinin (PHA)-P-activated PBMCs were infected either with the
reference lymphotropic HIV-1/LAI strain (Barre´-Sinoussi et al., 1983) or with
the reference macrophage-tropic HIV-1/Ba-L strain (Gartner et al., 1986).
These viruseswere amplified in vitro with PHA-P-activated bloodmononuclear
cells. Viral stocks (including clinical isolates) were titrated using PHA-P-
activated PBMCs, and 50% tissue culture infectious doses (TCID50) were
calculated using Ka¨rber’s formula (Ka¨rber, 1931). Viruses (125 TCID50) were
incubated for 30 min with five concentrations (1:5 dilutions between 500 nM
and 320 pM) of each of the molecules to be tested and added to 150,000
PBMCs (moi 0.001). Cell supernatants were collected at day 7 postinfection
and stored at 20C. In some cases, the compounds were added to the cells
prior to viral challenge. Viral replication was measured by quantifying reverse
transcriptase (RT) activity in the cell culture supernatants using the Lenti RT
Activity Kit (Cavisi) and AZT was used as reference anti-HIV-1 molecule. In
parallel, cytotoxicity was evaluated on day 7 in uninfected PHA-P-activated
PBMC using a colorimetric methyl-tetrazolium salt (MTS/PMS) assay (Prom-
ega). Experiments were performed in triplicate and 50, 70 and 90% effective
doses (ED) were calculated using SoftMaxPro software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.chembiol.2011.12.009.
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